Login
Password
Remember Me
New R&D agreement to expand Ziopharm’s TCR-T Program Ziopharm Oncology, an immuno-oncology company focused on developing end-to-end cost-effective solutions using its...
Fourth FDA approval for Vertex’s cystic fibrosis medicines The FDA has approved Trikafta™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis...
New version of SOPHiA Whole Exome Solution to accelerate rare disease characterization SOPHiA GENETICS, a leader in Data-Driven Medicine, has announced ...
More articles from NEWS
How to increase the number of European-based ATMP clinical trials? The latest report published by the Alliance for Regenerative Medicine (ARM),...
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report...
300 million people living with a rare disease worldwide An open-access article, written by Orphanet (coordinated by INSERM, the French National...
More articles from ANALYSES
Transforming DNA repair errors into assets A new bioinformatics tool, MHcut, developed by researchers in Kyoto, Japan, and Montreal, Canada, reveals that...
Accumulation of DNA mutations found in healthy liver leads to disease New insights into the journey from health to disease in...
New weapons against superbugs The rapid emergence of antimicrobial resistance is a matter of global concern. According to the WHO, particularly...
More articles from SCIENTIFIC NEWS
